clinical trial · NCT07493044
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
Guangzhou FineImmune Biotechnology Co., LTD.·phase1·recruiting·n = 15
Advanced Hepatocellular Carcinoma (HCC)GPC3 Positive Hepatocellular CarcinomaSuper CAR-T
brief summary
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
started
Mar 27, 2026
primary completion
Apr 30, 2028
completion
Jul 30, 2028
last updated
May 14, 2026
detailed description
After the subjects signed the informed consent form,the tumor tissue was detected by immunohistochemistry. The subjects could proceed to the subsequent clinical trial if the GPC3 immunohistochemistry was positive. Each subject received only one cell infusion.
official title
An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol